BROOMFIELD, Colo.--(BUSINESS WIRE)--Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced the initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing. VeriStrat® is a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC).
